Brian Lehman, MBA, MHA, RPh
The nature (positive, neutral, or negative) and level of impact of proposals on the biosimilar market will become clearer over time as the President directs HHS to take immediate action on some proposals, and as HHS takes future action, with feedback, on additional proposals.
May 18, 2018 @01:18 PM
CMS established a lower maximum copay for biosimilar and interchangeable biological products that is equivalent to the lower co-pay required for generic and preferred multiple source drugs.
Apr 16, 2018 @05:26 PM
Can lower cost biosimilars create a policy solution for seniors enrolled in the Medicare Coverage Gap Discount Program?
Jan 4, 2018 @01:46 PM
CMS is proposing a change to lower cost-sharing and improve enrollee incentives to choose biosimilars over reference biologics, and to reduce costs to both Medicare Part D enrollees and the Part D program. This objective would be accomplished by revising the definition of generic drug (§ 423.4) to include follow-on biologic products approved under the section 351(k) biosimilar pathway.
Nov 27, 2017 @03:10 PM
How will the 35% price discount by Merck/Samsung Bioepis on their infliximab biosimilar, compared with the reference, influence stakeholder uptake?
Aug 1, 2017 @01:19 PM
July 13, 2017, is the day for the review of FDA’s Oncology Drug Advisory Committee (ODAC) will review biologics license applications for biosimilars to trastuzumab (Herceptin) and bevacizumab (Avastin).
Jun 28, 2017 @07:41 PM
